North Growth Management Ltd. Has $7.17 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

North Growth Management Ltd. lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 18.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,000 shares of the medical research company’s stock after buying an additional 6,000 shares during the period. North Growth Management Ltd. owned about 0.08% of Charles River Laboratories International worth $7,168,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CRL. Wellington Management Group LLP increased its holdings in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. Allspring Global Investments Holdings LLC boosted its position in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Mizuho Securities USA LLC increased its position in Charles River Laboratories International by 2,336.4% in the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after purchasing an additional 92,895 shares during the last quarter. Premier Fund Managers Ltd raised its stake in shares of Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock worth $49,573,000 after purchasing an additional 90,000 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CRL. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. The Goldman Sachs Group reduced their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $200.79.

Charles River Laboratories International Stock Down 1.6 %

NYSE CRL opened at $163.65 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $159.65 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market cap of $8.37 billion, a PE ratio of 20.48, a PEG ratio of 6.47 and a beta of 1.37. The firm has a 50-day simple moving average of $180.61 and a 200 day simple moving average of $193.44.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.72 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 10.16 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).